The clinicopathological significances of LDHA and mutant p53 co-expression in gliomas
10.3969/j.issn.1006-5725.2017.14.007
- VernacularTitle:胶质瘤LDHA和突变型p53蛋白联合表达的临床病理学意义
- Author:
Miaoling LAI
;
Zhuofang HAO
;
Shizhang HUANG
;
Xiaoming OUYANG
;
Cheng ZHI
;
Hong SHEN
- Keywords:
gliomas;
lactate dehydrogenase-A subunit(LDHA);
mutant p53;
isocitrate dehydroge-nase1(IDH1);
differential diagnosis
- From:
The Journal of Practical Medicine
2017;33(14):2275-2280
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinicopathological significances of LDHA/mutant p53 co-expres-sion in gliomas. Methods According to the 2016 WHO CNS,archived 68 gliomas were collected and analyzed retrospectively. The co-expression of LDHA/mutant p53 was detected by immunohistochemical staining. Results High expression of LDHA alone was always found in high grade gliomas(48.5%). Mutant p53 high expression was usually observed in glioblastomas (26.5%). There was a close relationship between co-expression of LDHA/mutant p53 in glioblastoma(27.9%,P = 0.005),or gliomas with high histological grading(27.9%,P = 0.002). Conclusions Co-expression of LDHA/mutant p53 in tumor cells might be a specific immunohistochemical pheno-type of gliomas,and may help for distinguishing glioblastoma and other high grade gliomas from low grade gliomas.
